Last reviewed · How we verify
NCT05831462
De-escalation of Ticagrelor in Post PPCI
Phase 1, PHASE2 trial testing Ticagrelor 60mg in Ticagrelor in 400 participants. Status unknown.
31 March 2024
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 1 June 2023 |
| Primary completion | 31 March 2024 |
| Estimated completion | 1 May 2024 |
Drugs / interventions tested
- Ticagrelor 60mg — full drug profile →
Conditions studied
- Ticagrelor — all drugs for Ticagrelor →
Sponsor
Assiut University
Who can join
Adults 18 to 80, any sex, with Ticagrelor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary objective: to evaluate the efficacy and safety of De-escalation to lower dose Ticagrelor (60 mg BID) plus Aspirin (75 mg OD) versus continuation of standard dose Ticagrelor (90 mg BID) plus Aspirin (75 mg OD), 1 month after primary PCI for STEMI, in diabetic patients. Secondary objectives: To compare tolerability and discontinuation of Ticagrelor in both doses. To compare the 1ry safety \& efficacy endpoints in subgroups with different thrombotic/ischemic risk
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05831462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ticagrelor 60mg
Trials testing the same drug.
- NCT06228456 — Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention · Phase 4 · recruiting
- NCT04718025 — Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndro · Phase 3 · unknown
- NCT05283356 — Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation · Phase 4 · unknown
- NCT05210595 — Optimal Dosage of Ticagrelor in Korean Patients With AMI · Phase 4 · unknown
- NCT04483583 — Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI · Phase 4 · completed
Other recruiting trials for Ticagrelor
Currently open trials in the same condition.
- NCT07268859 — Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea · NA · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05831462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 26 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05831462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing